プラチナ製剤抵抗性または不応性卵巣がんに対するapatinib+エトポシド併用療法:第Ⅱ試験で奏効率は54%【Lancet Oncology】


Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study


 


 


 

コメント

Leave a comment

Your email address will not be published.


*